Revolutionary drops have already been approved in the US. They promise to replace reading glasses beyond eight hours of work when creating a “needle hole effect” similar to the diaphragm of a camera.
US regulatory agency FDA has already approved a new eye drug that promises to revolutionize the treatment of presbyopia – Condition that affects most people over 45 and that makes vision nearby.
The medicine is called Visit and consists of eye drops based on acetanylidecapable of restoring the nearby vision up to 10 hours with only one daily application.
Developed by pharmacist Lenz Therapeutics, Vizz acts causing a slight contraction of the pupil, creating a “needle hole effect” similar to the diaphragm of a camera, explains the. Narrowing significantly improves field depth, allowing you to focus closely objects with sharpness without demanding the effort of the eye muscles.
The latter is the big difference in vizz in the face of other treatments such as the, launched in 2021. Double-acting eye drops can improve vision closely, but can cause side effects such as overburnings or rare strain-strain problems due to ciliary muscle activation.
Vizz’s effectiveness and safety have been proven in three double -blind phase 3 clinical trials controlled by placebo. The first two tests involved 466 participants for six weeks and demonstrated visible vision improvements near just 30 minutes after applicationeffect that remained for 10 hours. The third rehearsal followed 217 participants for six months.
According to Lenz, no serious effects were recorded over more than 30,000 days of treatment. The most common side effects included mild eye irritation (20%), slightly cloudy vision (16%) and headaches (13%), all of which are considered transient and spontaneous resolution.
Presbyopia currently affects nearly 2 billion people worldwide and the World Health Organization (WHO) that the number exceeds 4 billion by 2050. With the approval of Vizz, a relief is expected for millions of adults who face reading difficulties or precision tasks.
The launch of the drug in the United States is scheduled for the last quarter of 2025, with future expansion to other markets such as Canada and China. There are no confirmed dates for Europe yet.
